BioSpace News Archive

Most drug addicts find it difficult to wean themselves away from the fatal substance and require a protracted therapy for that.

IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per Share $1.18 R&D Solutions quarterly net book-to-bill ratio 1.64x including pass throughs and 1.60x excluding pass throughs; contracted backlog including pass throughs grew 13.5 percent year-over-year to $20.5 billion

The healthcare industry is readily aspiring new technology that can enable caregivers to treat their patients better and the advent of intraoperative imaging has been in sync with it.

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs., Aug. 6 , before the open of the U.S. financial markets. The company also will host a webcast at 10:30 a.m. ET on Aug. 6 to discuss the results. The briefing

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced that a Fortune 100 global consumer packaged goods (CPG) company has deployed the LabVantage COVID-19 LIMS solution to ensure employee health and safety in the workplace.

Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma (GBM). T

Today, sedentary lifestyle is a parasite responsible for several health conditions in the expanding urban populace worldwide.

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares (“Common Shares”) from the Toronto Stock Exchange (“TSX”) in

Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for the on-going clinical trial, ASPIRE, for P-15L Bone Graft in a single level transforaminal lumbar interbody fusion (TLIF) surgery.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial markets close on Wednesday August 5, 2020. The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Wednesday August 5, 2020. To access the call, please d